Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations

被引:20
|
作者
Manley, Brandon J. [1 ]
Reznik, Ed [2 ]
Ghanaat, Mazyar [1 ]
Kashan, Mahyar [2 ]
Becerra, Maria F. [2 ]
Casuscelli, Jzefina [3 ]
Tennenbaum, Daniel [1 ]
Redzematovic, Almedina [4 ]
Carlo, Maria I. [4 ]
Sato, Yusuke [5 ]
Arcila, Maria [6 ]
Voss, Martin H. [4 ]
Feldman, Darren R. [4 ]
Motzer, Robert J. [4 ]
Russo, Paul [1 ]
Coleman, Jonathan [1 ]
Hsieh, James J. [2 ,4 ]
Hakimi, Ari A. [1 ]
机构
[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Genitourinary Oncol, Tampa, FL 33612 USA
[2] Washington Univ, Sch Med, Dept Med, Mol Oncol,Siteman Canc Ctr, St Louis, MO 63110 USA
[3] Ludwig Maximilians Univ Munchen, Dept Urol, Munich, Germany
[4] Mem Sloan Kettering Canc Ctr, Dept Med, Genitourinary Oncol Serv, 1275 York Ave, New York, NY 10021 USA
[5] Univ Tokyo, Grad Sch Med, Dept Urol, Tokyo, Japan
[6] Mem Sloan Kettering Canc Ctr, Dept Pathol, 1275 York Ave, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
Small renal masses; Genomic biomarkers; KDM5C; mutations; Risk stratification; PARTIAL NEPHRECTOMY; IMPACT; RISK; LESS; HETEROGENEITY; MANAGEMENT; ACCURACY; OUTCOMES; ASSAY; BAP1;
D O I
10.1016/j.urolonc.2017.10.012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Small renal masses (SRMs) with evidence of clear cell renal cell carcinoma (ccRCC) are understudied. Current algorithms for the management of SRMs include surgical resection, ablation, and active surveillance. We sought to identify genomic biomarkers that could potentially refine the management of ccRCC in SRMs, especially in patients being evaluated for active surveillance. Methods: We identified patients who had SRMs (4 cm or less) at time of surgery, had sequencing performed on their primary tumor and had a diagnosis of ccRCC. Patients were selected from 3 publicly available cohorts, The Cancer Genome Atlas (n = 110), University of Tokyo (n = 37), The International Cancer Genome Consortium (n = 31), and from our own institutional prospective database (n = 25). Among this cohort we analyzed mutations present in at least 5% of tumors, assessing for the enrichment of mutations and progression-free survival using the composite endpoint of recurrence or death of disease. Analysis was adjusted for multiple testing. A Cox regression model was used to assess clinical variables with significant mutations. Results: In total, 203 patients were available for analysis. Median follow-up was 43.1 months among survivors. Mutations in VHL, PBRM1, SETD2, BAP1, KDM5C, and MTOR were present in more than 5% of tumors. Twenty-three patients (11.3%) had recurrence or died of their disease. Mutations in KDM5C were associated with inferior survival from either recurrence or death from disease, adjusted P0.033. Conclusions: We identified mutations in SRMs in ccRCC that are associated with recurrence and lethality. The strongest association was seen in those with KDM5C mutations. Use of these genomic biomarkers may improve stratification of patients with SRMs and for those who may be appropriate for active surveillance. Prospective evaluation of these markers is needed. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码:12 / 17
页数:6
相关论文
共 50 条
  • [1] Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations
    Manley, Brandon
    Reznik, Ed
    Becerra, Maria
    Casuscelli, Jozefina
    Tennenbaum, Daniel
    Ghanaat, Mazyar
    Kashan, Mahyar
    Redzematovic, Almedina
    Sato, Yusuke
    Arcila, Maria
    Voss, Martin
    Feldman, Darren
    Motzer, Robert
    Russo, Paul
    Coleman, Jonathan
    Hsieh, James
    Hakimi, Ari
    Voss, Martin
    Feldman, Darren
    Motzer, Robert
    Russo, Paul
    Coleman, Jonathan
    Hsieh, James
    Hakimi, Ari
    [J]. BJU INTERNATIONAL, 2016, 118 : 4 - 5
  • [2] CHARACTERIZING RECURRENT AND LETHAL SMALL RENAL MASSES IN CLEAR CELL RENAL CELL CARCINOMA USING SOMATIC MUTATIONS
    Manley, Brandon
    Reznik, Ed
    Becerra, Maria
    Casuscelli, Jozefina
    Tennenbaum, Daniel
    Ghanaat, Mazyar
    Kashan, Mahyar
    Redzematovic, Almedina
    Sato, Yusuke
    Arcila, Maria
    Voss, Martin
    Feldman, Darren
    Russo, Paul
    Coleman, Jonathan
    Hsieh, James
    Hakimi, Ari
    [J]. JOURNAL OF UROLOGY, 2017, 197 (04): : E492 - E493
  • [3] CLINICAL FEATURES OF RECURRENT SOMATIC MUTATIONS IN CLEAR CELL RENAL CELL CARCINOMA: A LARGE COHORT
    Manley, Brandon J.
    Casuscelli, Jozefina
    Tennenbaum, Daniel M.
    Becerra, Maria F.
    Redzematovic, Almedina
    Arcila, Maria E.
    Voss, Martin H.
    Feldman, Darren R.
    Coleman, Jonathan A.
    Russo, Paul
    Motzer, Robert J.
    Hsieh, James J.
    Hakimi, A. Ari
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E919 - E919
  • [4] CORRELATING IMMUNE CELL INFILTRATION PATTERNS WITH RECURRENT SOMATIC MUTATIONS IN CLEAR CELL RENAL CELL CARCINOMA
    Chakiryan, Nicholas
    Hajiran, Ali
    Kim, Youngchul
    Chahoud, Jad
    Spiess, Philippe
    Wang, Liang
    Moran-Segura, Carlos
    Nguyen, Jonathan
    Dhillon, Jasreman
    Mule, James
    Manley, Brandon
    [J]. JOURNAL OF UROLOGY, 2021, 206 : E847 - E848
  • [5] Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma br
    Chakiryan, Nicholas H.
    Hajiran, Ali
    Kim, Youngchul
    Aydin, Ahmet M.
    Zemp, Logan
    Katende, Esther
    Nguyen, Jonathan
    Fan, Wenyi
    Cheng, Chia -Ho
    -Blanco, Neale Lopez
    Chahoud, Jad
    Spiess, Philippe E.
    Fournier, Michelle
    Dhillon, Jasreman
    Wang, Liang
    Moran-Segura, Carlos
    Mule, James
    Du, Dongliang
    Yoder, Sean J.
    Berglund, Anders
    Teer, Jamie K.
    Manley, Brandon J.
    [J]. EUROPEAN UROLOGY FOCUS, 2022, 8 (03): : 784 - 793
  • [6] Integration of Recurrent Somatic Mutations with Clinical Outcomes: A Pooled Analysis of 1049 Patients with Clear Cell Renal Cell Carcinoma
    Manley, Brandon John
    Zabor, Emily C.
    Casuscelli, Jozefina
    Tennenbaum, Daniel M.
    Redzematovic, Almedina
    Becerra, Maria F.
    Benfante, Nicole
    Sato, Yusuke
    Morikawa, Teppei
    Kume, Haruki
    Fukayama, Masashi
    Homma, Yukio
    Ogawa, Seishi
    Arcila, Maria E.
    Voss, Martin H.
    Feldman, Darren R.
    Coleman, Jonathan A.
    Reuter, Victor E.
    Motzer, Robert J.
    Russo, Paul
    Hsieh, James J.
    Hakimi, A. Ari
    [J]. EUROPEAN UROLOGY FOCUS, 2017, 3 (4-5): : 421 - 427
  • [7] IMPACT OF SOMATIC MUTATIONS ON PATTERNS OF METASTASIS IN CLEAR CELL RENAL CELL CARCINOMA
    Becerra, Maria
    Sanchez-Vega, Francisco
    Reznik, Ed
    Manley, Brandon
    Kashan, Mahyar
    Ghanaat, Mazyar
    Casuscelli, Jozefina
    Redzematovic, Almedina
    Mendonca, Shawn
    Arcila, Maria
    Coleman, Jonathan
    Russo, Paul
    Hsieh, James
    Hakimi, A. Ari
    [J]. JOURNAL OF UROLOGY, 2017, 197 (04): : E493 - E494
  • [8] IDENTIFICATION OF RECURRENT SOMATIC SPLICE SITE VARIANTS ACROSS MULTIPLE CLEAR CELL RENAL CELL CARCINOMA COHORTS
    Chakiryan, Nicholas
    Robinson, Timothy
    Du, Dongliang
    Hajiran, Ali
    Zemp, Logan
    Kim, Youngchul
    Chahoud, Jad
    Spiess, Philippe
    Wang, Liang
    Mule, James
    Manley, Brandon
    [J]. JOURNAL OF UROLOGY, 2021, 206 : E709 - E710
  • [9] PROTEOGENOMIC AND CLINICAL IMPLICATIONS OF RECURRENT SPLICE VARIANTS IN CLEAR CELL RENAL CELL CARCINOMA
    Chang, Andrew
    Stewart, Paul
    Chakiryan, Nicholas
    Soupir, Alex
    Tian, Yijun
    Du, Dongliang
    Teer, Jamie
    Kim, Youngchul
    Spiess, Philippe
    Chahoud, Jad
    Zhang, Yonghong
    Koomen, John
    Berglund, Anders
    Robinson, Timothy
    Wang, Liang
    Manley, Brandon
    [J]. JOURNAL OF UROLOGY, 2022, 207 (05): : E33 - E33
  • [10] Recurrent Chylothorax in Renal Cell Carcinoma
    Beg, Moeezullah
    Arif, Hamza
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (07)